Virtual Library
Start Your Search
P. Xing
Author of
-
+
P2.03a - Poster Session with Presenters Present (ID 464)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03a-024 - The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non-Small Cell Lung Cancer: A Meta-Analysis (ID 3956)
14:30 - 14:30 | Author(s): P. Xing
- Abstract
Background:
This study was conducted to extract a specific conclusion about the clinical efficacy of paclitaxel liposome in non-small cell lung cancer (NSCLC).
Methods:
Pubmed, Embase and Chinese National Knowledge Infrastructure (CNKI) databases were searched for potential relevant articles. Relative risks (RRs) with 95% confidence intervals (CIs) represented the influences of paclitaxel liposome on the objective response rate (ORR), disease control rate (DCR) and adverse events. I2＞50% and P＜0.05 indicate significant heterogeneity. If there existed heterogeneity, then the random-effects model was used. Otherwise, the fixed-effects model was adopted. Sensitivity analysis was performed to test the robustness of overall results. Begg’s funnel plot and Egger’s linear regression test were used to evaluate the potential publication bias.
Results:
The results indicated that paclitaxel liposome could improve the ORR of NSCLC patients (RR=1.22, 95%CI=1.03-1.44). Moreover, we observed that paclitaxel liposome was related with enhanced DCR as well (RR=1.08, 95%CI=1.01-1.16). The influences of paclitaxel liposome on the occurrences of adverse events were analyzed. The outcome suggested that paclitaxel liposome could inhibit the occurrences of muscle pain during the therapy (RR=0.34, 95%CI=0.26-0.45). Besides, onset of rash could also be inhibit by paclitaxel liposome (RR=0.17, 95%CI=0.08-0.35). Sensitivity analysis indicated that the overall results were robust. The funnel plot seemed to be symmetry (P=0.669).
Conclusion:
Paclitaxel liposome is an effective anti-cancer drugs for NSCLC patients.
-
+
P2.03b - Poster Session with Presenters Present (ID 465)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-018 - Clinical Data from the Real World: Efficacy of Crizotinib in Chinese Patients with Advanced ALK+ Non-Small Cell Lung Cancer and Brain Metastases (ID 4091)
14:30 - 14:30 | Author(s): P. Xing
- Abstract
Background:
Brain metastasis in NSCLC patients is often considered as a terminal stage of advanced disease. Crizotinib is a small-molecule tyrosine kinase inhibitor (TKI) for ALK-rearranged NSCLC patients that can improve systemic outcomes. Herein, a retrospective analysis of Crizotinib was performed in advanced ALK-rearranged NSCLC patients with brain metastases, to explore how Crizotinib affects the control of brain metastases and the overall prognosis in Chinese population in the real world.
Methods:
Advanced NSCLC patients with brain metastases who underwent Crizotinib treatment at the Cancer Hospital of the Chinese Academy of Medical Sciences between April 2013 and April 2015 were included. ALK translocation was determined by FISH, Ventana IHC test or RT-PCR. Brain metastases were diagnosed by CT or MRI.
Results:
A total of 34 patients were enrolled, of whom 20 patients had baseline brain metastases at the initiation of Crizotinib treatment. For patients with baseline metastases, overall survival (OS) after brain metastases was significantly longer, compared with those developing brain metastases during Crizotinib treatment (median OS, not reached vs. 10.3 months, p = 0.001). Among all the patients treated with chemotherapy at the first line, OS after brain metastases in patients with baseline brain metastases was significantly superior than those without (p = 0.023). Whereas, patients receiving Crizotinib at the first line with baseline brain metastases didn’t demonstrate such superior (p = 0.089). Among patients who developed brain metastases during Crizotinib treatment, for those receiving chemotherapy at the first line, though the result was not significant by the cut-off date, time to brain metastases was longer, compared with patients receiving Crizotinib at the first line (median time to brain metastases, 17.1 months vs. 10.5 months, p = 0.072).Figure 1
Conclusion:
Chinese ALK-rearranged NSCLC patients with baseline brain metastases may benefit more from Crizotinib than those developing brain metastases during Crizotinib treatment.
